Coeptis Financial Statements From 2010 to 2026

COEP Stock  USD 13.22  0.08  0.60%   
Analyzing historical trends in various income statement and balance sheet accounts from Coeptis Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Coeptis Therapeutics' valuation are summarized below:
Gross Profit
173.2 K
Market Capitalization
68.2 M
Enterprise Value Revenue
139.1453
Revenue
263.6 K
Earnings Share
(6.87)
There are currently one hundred twenty fundamental signals for Coeptis Therapeutics that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Coeptis Therapeutics' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction.
Check Coeptis Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coeptis Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 660.6 K, Other Operating Expenses of 13.7 M or Total Operating Expenses of 13.1 M, as well as many indicators such as Price To Sales Ratio of 3 K, Dividend Yield of 0.0 or PTB Ratio of 3.63. Coeptis financial statements analysis is a perfect complement when working with Coeptis Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Coeptis Stock
Check out the analysis of Coeptis Therapeutics Correlation against competitors.
To learn how to invest in Coeptis Stock, please use our How to Invest in Coeptis Therapeutics guide.

Coeptis Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.8 M10.2 M3.2 M
Slightly volatile
Short and Long Term Debt Total1.5 M1.6 M893.3 K
Slightly volatile
Total Current Liabilities5.4 M5.2 M1.7 M
Slightly volatile
Accounts Payable1.5 M1.5 M1.3 M
Slightly volatile
Cash582.2 K612.8 K688.1 K
Slightly volatile
Non Current Assets Total9.5 MM2.3 M
Slightly volatile
Cash And Short Term Investments582.2 K612.8 K688.1 K
Slightly volatile
Common Stock Shares Outstanding2.1 M2.2 M4.9 M
Slightly volatile
Liabilities And Stockholders Equity10.8 M10.2 M3.2 M
Slightly volatile
Total Liabilities6.1 M5.8 MM
Slightly volatile
Total Current Assets1.6 M1.2 M1.4 M
Slightly volatile
Short Term Debt1.2 M1.4 M729.2 K
Slightly volatile
Intangible Assets592 K623.2 K2.8 M
Slightly volatile
Common Stock18119114.1 K
Slightly volatile
Non Currrent Assets Other1.7 M1.8 M866.5 K
Slightly volatile
Other Assets4.7 M4.5 M1.2 M
Slightly volatile
Property Plant Equipment64.5 K36.6 K34.7 K
Slightly volatile
Other Current Liabilities2.4 M2.3 M768 K
Slightly volatile
Current Deferred Revenue734.3 K1.1 M406.6 K
Slightly volatile
Net Receivables47.1 K44.8 K15.3 K
Slightly volatile
Property Plant And Equipment Net67.8 K68.8 K69.5 K
Slightly volatile
Long Term Debt128.2 K135 K236.1 K
Pretty Stable
Non Current Liabilities Total1.1 M607.3 K485.9 K
Slightly volatile
Capital Lease Obligations63.3 K70.4 K57.9 K
Pretty Stable
Other Current Assets626 K596.2 K161 K
Slightly volatile
Property Plant And Equipment Gross92.1 K97.8 K84.9 K
Pretty Stable
Short and Long Term Debt1.3 M1.1 M1.7 M
Slightly volatile
Capital Stock1831932.2 K
Slightly volatile

Coeptis Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization660.6 K934.8 K565.4 K
Very volatile
Other Operating Expenses13.7 M11.6 M10.2 M
Slightly volatile
Total Operating Expenses13.1 M10.4 M9.4 M
Slightly volatile
Selling General Administrative808.5 K851.1 KM
Very volatile
Selling And Marketing Expenses9.5 K14.6 K7.9 K
Slightly volatile
Research DevelopmentM2.7 M807.7 K
Slightly volatile
Cost Of Revenue979.6 K1.2 M957 K
Very volatile
Reconciled Depreciation838.7 K1.2 M534.1 K
Slightly volatile

Coeptis Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow582.2 K612.8 K688.1 K
Slightly volatile
Begin Period Cash FlowM1.7 M639.5 K
Slightly volatile
Depreciation604.9 K1.2 M333.4 K
Slightly volatile
Other Cashflows From Investing Activities509.6 K573.3 K625.8 K
Slightly volatile
Issuance Of Capital Stock3.5 M3.6 M2.3 M
Slightly volatile
Dividends Paid62.1 K69.8 K76.2 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales RatioK3.1 K88.6 K
Slightly volatile
Days Sales Outstanding207233254
Slightly volatile
Average Payables93.2 K104.9 K114.5 K
Slightly volatile
Stock Based Compensation To Revenue20.2422.7724.8545
Slightly volatile
Capex To Depreciation3.133.523.8424
Slightly volatile
EV To SalesK3.2 K88.7 K
Slightly volatile
Payables Turnover0.890.941.7712
Slightly volatile
Sales General And Administrative To Revenue150169184
Slightly volatile
Research And Ddevelopement To Revenue0.0960.10.1132
Slightly volatile
Capex To Revenue18.6621.022.9212
Slightly volatile
Cash Per Share0.30.320.2099
Slightly volatile
Days Payables Outstanding444513515
Slightly volatile
Income Quality0.670.721.5607
Slightly volatile
Intangibles To Total Assets0.06650.06990.4055
Slightly volatile
Current Ratio0.370.210.2396
Slightly volatile
Receivables Turnover1.131.271.387
Slightly volatile
Capex Per Share1.371.541.6821
Slightly volatile
Average Receivables11 K21.2 K7.7 K
Slightly volatile
Revenue Per Share0.06930.0660.0262
Slightly volatile
Interest Debt Per Share1.021.073.497
Slightly volatile
Debt To Assets0.170.181.0348
Pretty Stable
Operating Cycle207233254
Slightly volatile
Days Of Payables Outstanding444513515
Slightly volatile
Quick Ratio0.370.210.2396
Slightly volatile
Cash Ratio0.10.110.2013
Slightly volatile
Days Of Sales Outstanding207233254
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.251.3651
Slightly volatile
Fixed Asset Turnover1.112.121.014
Slightly volatile
Debt Ratio0.170.181.0348
Pretty Stable
Price Sales RatioK3.1 K88.6 K
Slightly volatile
Asset Turnover0.01210.01270.0703
Slightly volatile

Coeptis Fundamental Market Drivers

Coeptis Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Coeptis Therapeutics Financial Statements

Coeptis Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Coeptis Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Coeptis Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coeptis Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 M734.3 K
Cost Of Revenue1.2 M979.6 K
Stock Based Compensation To Revenue 22.77  20.24 
Sales General And Administrative To Revenue 169.42  150.32 
Research And Ddevelopement To Revenue 0.10  0.10 
Capex To Revenue 21.00  18.66 
Revenue Per Share 0.07  0.07 
Ebit Per Revenue(168.55)(176.98)

Pair Trading with Coeptis Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Coeptis Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Coeptis Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Coeptis Stock

  0.55DBVT DBV TechnologiesPairCorr
  0.55MARUF Marubeni Earnings Call This WeekPairCorr
  0.53BFDE Bedford EnergyPairCorr
  0.42VNDA Vanda PharmaceuticalsPairCorr
  0.37CAPR Capricor TherapeuticsPairCorr
The ability to find closely correlated positions to Coeptis Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Coeptis Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Coeptis Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Coeptis Therapeutics to buy it.
The correlation of Coeptis Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Coeptis Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Coeptis Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Coeptis Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Coeptis Stock Analysis

When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.